Pancreatic Cancer Research

ResearcherKagawa UniversityActive in the last 2 years

Akihito Tsuji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4034-1945; OpenAlex author ID A5006196118, A5062868734. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 9

  1. A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectabl… Co-author DOI 10.1245/s10434-025-18714-7↗
  2. ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and… Co-author DOI 10.1245/s10434-025-18894-2↗
  3. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002011↗
  4. FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study). Last author DOI 10.21873/cdp.10083↗
  5. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrosp… Last author DOI 10.1159/000517244↗
  6. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyy033↗
  7. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  8. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2016.436↗
  9. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancrea… Co-author DOI 10.1007/s00280-016-3026-6↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keiichi Okano · 5 shared papers, 2018–2026 · strength 0.90
  2. Hironobu Suto · 4 shared papers, 2018–2026 · strength 0.76
  3. Minoru Oshima · 4 shared papers, 2018–2026 · strength 0.76
  4. Toru Shibata · 3 shared papers, 2022–2026 · strength 0.68
  5. Yasuyuki Suzuki · 3 shared papers, 2018–2022 · strength 0.35
  6. Tsutomu Masaki · 2 shared papers, 2018–2022 · strength 0.21
  7. Yukimasa Hatachi · 1 shared paper, 2022 · strength 0.17
  8. Hisateru Yasui · 1 shared paper, 2022 · strength 0.17
  9. Shigeo Takahashi · 1 shared paper, 2022 · strength 0.14
  10. Kotone Hayuka · 1 shared paper, 2021 · strength 0.14
  11. Shinichi Ohkawa · 2 shared papers, 2017–2018 · strength 0.12
  12. Haruo Iguchi · 2 shared papers, 2017–2018 · strength 0.12
  13. Tatsuya Ioka · 2 shared papers, 2017–2018 · strength 0.12
  14. Junji Furuse · 2 shared papers, 2017–2018 · strength 0.12
  15. Mina Nagao · 1 shared paper, 2018 · strength 0.07
  16. Teruhiko Yoshida · 1 shared paper, 2018 · strength 0.06
  17. Hiroshi Ishii · 1 shared paper, 2018 · strength 0.06
  18. Masafumi Ikeda · 1 shared paper, 2018 · strength 0.06
  19. Yasunori Sato · 1 shared paper, 2018 · strength 0.06
  20. Hideki Ueno · 1 shared paper, 2018 · strength 0.06
  21. Takuji Okusaka · 1 shared paper, 2018 · strength 0.06
  22. Hironobu Minami · 1 shared paper, 2016 · strength 0.05
  23. Meiko Nishimura · 1 shared paper, 2016 · strength 0.05
  24. Taketo Yamaguchi · 1 shared paper, 2017 · strength 0.05
  25. Yuh Sakata · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.